SciSparc Ltd.
SPRCHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, SciSparc Ltd. focuses on Biotechnology services and products. SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. With a market capitalization of $3.1M, it sits in micro-cap territory. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Market Cap
$3.1M
Beta
2.44
P/E (TTM)
0.05
P/E (Fwd)
—
EPS (TTM)
$98.07
EPS (Fwd)
—
ROE
-178.4%
ROA
-60.7%
Cash
$4.6M
Total Debt
$366,000
Free CF
$833,000
52W Change
-67.3%
Annual Financials
Cash vs Debt
Where SPRC stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, SPRC finished 4.38% below its 150-day moving average ($5.93) and 30.85% below its 200-day moving average ($8.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SPRC overbought or oversold?
At the September 2, 2026 close, SPRC's RSI(14) was 29.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
SciSparc Ltd. holds $4.6M in cash against $366K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $833K supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -178.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.3M (2022) to $856K (2025), a 36% decline worth watching.
With a beta above 1.5, SPRC tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, SPRC has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing SPRC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.